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SUMMARY
Proteasome-catalyzed peptide splicing (PCPS) gen-
erates peptides that are presented by MHC class I
molecules, but because their identification is chal-
lenging, the immunological relevance of spliced pep-
tides remains unclear. Here, we developed a reverse
immunology-based multi-level approach to identify
proteasome-generated spliced epitopes. Applying
this strategy to a murine Listeria monocytogenes
infection model, we identified two spliced epitopes
within the secreted bacterial phospholipase PlcB
that primed antigen-specific CD8+ T cells in
L. monocytogenes-infected mice. While reacting to
the spliced epitopes, these CD8+ T cells failed to
recognize the non-spliced peptide parts in the
context of their natural flanking sequences. Thus,
we here show that PCPS expands the CD8+ T cell
response against L. monocytogenes by exposing
spliced epitopes on the cell surface. Moreover, our
multi-level strategy opens up opportunities to sys-
tematically investigate proteins for spliced epitope
candidates and thus strategies for immunotherapies
or vaccine design.
INTRODUCTION
CD8+ T cell responses play an important role in the clearance
of intracellular pathogens and in protection from subsequent
infections. CD8+ T cells react to epitopes presented by major
histocompatibility complex class I (MHC class I) molecules at
the cell surface. Epitope generation usually starts through pro-
teasomal processing of pathogen-derived intracellular proteins.
Peptides released by the proteasome are translocated by the
transporter associated with antigen processing (TAP) into the
endoplasmic reticulum (ER), where theymay undergo N-terminal
trimming by ER-resident aminopeptidases (ERAPs) (Cascio
et al., 2001; Rock et al., 1994; Sijts and Kloetzel, 2011) and are
loaded onto MHC class I molecules for presentation at the cell
surface (Groettrup et al., 2010).
Given the central role of proteasomes in MHC class I antigen
processing, their catalytic activity plays a fundamental role in
shaping the pathogen-derived peptide repertoire toward which
CD8+ T cells may react. The catalytic activity of proteasomes
is displayed by three subunits, b1, b2, and b5, which are re-
placed by the induced catalytic subunits b1i/LMP2, b2i/
MECL1, and b5i/LMP7 when cells are exposed to an inflamma-
tory milieu (Groettrup et al., 2010; Sijts and Kloetzel, 2011). The
changes in the catalytic subunit composition induce subtle
modifications in conformation of the active sites, which affect
proteasome proteolytic dynamics, and have consequences for
the quantities of peptides produced (Arciniega et al., 2014; Liepe
et al., 2015; Mishto et al., 2014; Ruschak and Kay, 2012; Sijts
et al., 2000). Proteasomes can simply hydrolyze the peptide
bonds of the antigen, thereby releasing canonical non-spliced
peptides, or splice two distal fragments of the antigen, thereby
generating peptides with a novel sequence (Vigneron et al.,
2004). The latter mechanism is called proteasome-catalyzed
peptide splicing (PCPS) (Mishto et al., 2012).
Despite the well-established crucial role of proteasomes in
MHC class I antigen processing, the immunological relevance
of PCPS is still a matter of debate, in part because only a few
proteasome-generated spliced epitopes, mainly derived from
tumor-associated antigens (Dalet et al., 2011; Ebstein et al.,
2016; Hanada et al., 2004; Michaux et al., 2014; Vigneron et al.,
2004; Warren et al., 2006), have been described so far. Some
recent studies, however, hint at the importance of PCPS in
MHC class I antigen presentation. Indeed, based on mass spec-
trometry (MS) analyses, approximately one-third of the peptides
presented by MHC class I molecules on human lymphoblastoid
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and fibroblast cells are proteasome-generated spliced peptides,
and one-third of self-antigens presented byMHCclass I on these
cells are represented by spliced peptides only (Liepe et al., 2016).
Such a significant increase in the variety of peptides potentially
recognized by CD8+ T cells due to PCPS is also strengthened
by their amount, which has been calculated in the order of one
fourth of the MHC class I-restricted self-peptides (Liepe et al.,
2016). This is in agreement with the amount of tumor-associated
spliced epitopes presented by human MHC class I molecules at
the cell surface, as shown for the gp100mel antigen (Ebstein et al.,
2016).
The relevance of PCPS in the cell-mediated immune response
during infections is still unknown. We recently described cross-
reactivity of CD8+ T cells, primed during L. monocytogenes by
the dominant listeriolysin O (LLO)-derived epitope LLO296–304, to-
ward the spliced epitope LLO294/297–304 (Platteel et al., 2016).
Nevertheless, so far, no clear evidence that PCPS leads to spliced
peptide-specific CD8+ T cell responses during infection has been
found. The scarcity of knowledge on the role of PCPS in immune
recognition illustrates the difficulty of identifying immunologically
relevant spliced epitopes, which lies in adopting a reverse immu-
nology approach, requiring a complex in silico-in vitro workflow.
Topropel further investigation into the role of PCPS in antigen pro-
cessing, we have developed a multi-level spliced epitope identifi-
cation strategy, which we tested in the murine L. monocytogenes
infection model. L. monocytogenes is a Gram-positive bacterium
that primarily infects phagocytes and then mobilizes the host cell
cytoskeleton to spread to neighboring cells. To enter the cytosol
of infected cells, the bacteria secreteLLOand the phospholipases
PlcA/phosphatidylinositol-specific phospholipase C (PI-PLC) and
PlcB/phosphatidylcholine-preferring phospholipase C (PC-PLC)
(Bielecki et al., 1990; Pamer, 2004; Portnoy et al., 1992). Bacterial
clearanceduringL.monocytogenes infection ismediatedbyCD8+
T cells specific for the secreted bacterial proteins. Therefore, to
test and validate our spliced epitope identification approach, we
decided to use the secreted PlcA and PlcB proteins as model
antigens.
RESULTS
Identification of L. monocytogenes-Derived Spliced
Epitope Candidates
LLO296–304 and its spliced variant LLO294/297–304 are the main,
known, targets of CD8+ T cells responding to L. monocytogenes
infection in C57BL/6 mice (Geginat et al., 2001; Platteel et al.,
2016). The PlcA and PlcB antigens used in this study to develop
a reverse immunology-based spliced epitope prediction method
possess 317 residues and 292 residues, respectively. These two
proteins lack knownH-2Kb presented epitopes. To identify poten-
tial spliced epitopes, we computed all possible 8-mer and 9-mer
non-spliced and spliced peptides from the two antigens (Figure 1).
Here, the peptide length was restricted to reduce the number of
potential epitopes since 8-mer and 9-mer peptides represent the
majority of the mouseMHC class I ligandome. The resulting data-
base contained in total 1.563 106 sequences (Figures 2A and 2B).
We then reduced the number of sequences by introducing further
restrictions, which were based on previous studies. In particular,
among the peptide candidates, we (1) set a maximal distance of
40 residues between the two splice reactants (i.e., the intervening
sequence) and (2) excluded spliced peptides that were generated
by binding of splice-reactants derived from two molecules of the
same antigen (i.e., trans PCPS), as suggested by Dalet et al.
(2010). Thus, only cis-spliced peptides, i.e., peptides generated
from fragments of the same molecule, were included. This
reduced database contained 4.67 3 105 entries for potential
8–9-mer spliced peptides and 1,188 entries for the potential
8–9-mer non-spliced peptides (Figures 2A and 2B). Because we
were interested in antigenic peptides efficiently presented in the
H-2Kb cleft, we further reduced the database by selecting only
those peptides that were predicted to bind H-2Kb molecules
with an IC50 < 100nMusing the algorithm stabilizedmatrixmethod
(SMM) (Peters andSette, 2007) (Figures 1, 2C, and2D). This selec-
tion step reduced the PlcA and PlcB candidate list to 989 spliced
peptides and five non-spliced peptides. From these, we selected
the 22 peptides with the lowest predicted IC50, i.e., lower than
16 nM, which were all spliced peptides (Table 1; Figures S1 and
S2), for further testing in ex vivo CD8+ T cell recognition assays
(Figure 1).
In summary, we applied several reduction steps in silico based
on previously collected experimental evidence in order to obtain
a candidate list of 22 predicted PlcA- and PlcB-spliced epitopes,
starting from 1.56 3 106 potential spliced peptides. This led to
progressive emergence of a peptide sequence pattern in the
reduced databases, which included the known H-2Kb anchor
sites (Falk et al., 1991) (Figures 2E and 2F).
Specific CD8+ T Cells Are Activated by PlcB-Derived and
Proteasome-Generated Spliced Epitopes in
L. monocytogenes Infection
To test the immunogenicity of the selected antigenic spliced
epitope candidates, C57BL/6 mice were infected intravenously
(i.v.) with 2,000 colony forming units (CFUs) L. monocytogenes.
At day 7, the peak of the response (Busch et al., 1998), their sple-
nocytes were isolated and frequencies of CD8+ T cells producing
interferon (IFN)-g upon recognition of the spliced peptides were
measured ex vivo, by intracellular cytokine staining and flow
cytometry (Figure 3A). Two spliced PlcB epitope candidates,
i.e., PlcB189–191/163–167 and PlcB189–192/164–167, as well as the
known immunodominant non-spliced epitope LLO296–304, stimu-
lated IFN-g production in a significant number of CD8+ T cells
(Figure 3B), indicating that these peptides are recognized by
CD8+ T cells responding to L. monocytogenes infection.
To confirm that the PlcB-derived spliced epitopes were gener-
ated by the proteasome, we performed in vitro digestions of the
synthetic substrate PlcB159–171/185–196 with 20S proteasomes
purified from the spleens of L. monocytogenes infected or unin-
fected mice. The substrate sequences were derived from the
original PlcB protein, although part of the intervening sequence
(PlcB172–184) was removed to facilitate the in vitro reaction as
previously demonstrated (Dalet et al., 2010). MS analysis of the
digests demonstrated the proteasome-mediated generation of
the spliced epitopes PlcB189–191/163–167 and PlcB189–192/164–167
(Figure S3). By applying the quantitative method QME (quantifi-
cation with minimal effort) to samples collected at different
time intervals following in vitro digestion of PlcB159–171/185–196,
we measured the generation kinetics of the spliced epitopes
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PlcB189–191/163–167 and PlcB189–192/164–167 (Figure S4). No
remarkable differences in generation kinetics of the two spliced
epitopes were detected between reactions carried out by pro-
teasomes purified from either uninfected or infected mouse
spleens.
Thus,weconfirmed that the splicedepitopesPlcB189–191/163–167
andPlcB189–192/164–167 canbegeneratedby the proteasome, both
early in infection when proteasome composition has not yet been
changed as result of the inflammatory milieu (see results with pro-
teasomes of uninfected mouse spleens) and in later stages of
infection.
CD8+ T Cells Specific for the PlcB-Derived Spliced
Epitopes Do Not Cross-React against Non-spliced
Peptides in L. monocytogenes Infection
CD8+ T cell responses to PlcB189–191/163–167 and
PlcB189–192/164–167, detected ex vivo, may have been primed by
non-spliced epitope variants rather than by the spliced epitopes.
To rule out this possibility, we compared the frequencies of CD8+
T cells in L. monocytogenes infected mouse spleens specific for
the spliced epitopes PlcB189–191/163–167 and PlcB189–192/164–167,
to the response elicited by the two non-spliced peptides
PlcB160–167 and PlcB189–196, which shared part of the N or C ter-
minus with the spliced epitopes (their generation kinetics are
shown in Figure S4). Only the spliced epitopes were specifically
recognized by CD8+ T cells primed during L. monocytogenes
infection (Figure 4A).
To further investigate the possibility that CD8+ T cells, specific
for the two spliced epitopes, were primed by Listeria-derived
non-spliced peptides, we adapted an in silico analysis method,
described by Calis et al. (2012). We first computed all spliced
epitope-related peptides that could potentially prime cross-
reactive CD8+ T cells, due to T cell receptor (TCR) degeneracy.
It has been shown that the amino acid residues at the anchor
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Figure 1. Reverse-Immunology Approach to Identifying Immunogenic Spliced Peptides In Vivo
The systematic identification of immunogenic peptides requires a combined in silico-in vitro approach. Illustrated is the identification of non-spliced peptides
(pink arrows) and identification of spliced peptides (blue arrows). For the latter, we first computed the complete list of theoretically possible spliced peptides from
a given antigen and reduced this step by step to a number of spliced peptides predicted to bind to the H-2Kb molecule. The final candidate list of epitopes then
was tested ex vivo. C57BL/6micewere infectedwith L.monocytogenes. After 7 days, the splenocytes were isolated and incubatedwith the spliced peptides from
the final candidate list. Peptides that triggered IFN-g production in CD8+ T cells ex vivo (i.e., CD8+ IFN-g+ T cells) were targeted by the L. monocytogenes-induced
CD8+ T cell response in vivo.
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sites (3, 5, and 8 for the H2-Kb molecule) as well as the positions
1, 2, and 8 (for 9-mer) and 2, 3, and 8 (for 8-mer) are often irrel-
evant for efficient TCR recognition (Falk et al., 1991; Matsumura
et al., 1992). We therefore computed all theoretical peptide se-
quences that followed the patterns ISXPXYKX, XXYPFYKX,
and IXXPFYKX for the peptide PLCb189–192/164–167 (ISYPFYKL)
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(A and B) All possible 8-mer and 9-mer non-spliced and spliced peptides were computed for (A) PlcA and (B) PlcB. Shown is the reduction of the number of
potential peptides based on the spliced peptide characteristics. It is often possible to produce the same sequence through different PCPS events from the same
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(C andD) For all 8-mer and 9-mer non-spliced peptides and for all 8-mer and 9-mer cis-spliced peptideswith amaximum intervening sequence length of 40 amino
acids the IC50 of binding to the H-2K
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and ISXAXYKX, XXYAFYKX, and IXXAFYKX for the peptide
PLCb189–191/163–167 (ISYAFYKL), where X could be any of the
20 amino acids. This resulted in 7,999 related peptides per
candidate, which could theoretically prime CD8+ T cells re-
active also to the spliced epitope-specific, if any of these pep-
tides were generated in vivo. However, none of these theoretical
peptide sequences could be found in the L. monocytogenes
non-spliced proteome (represented by 2,844 protein entries)
(data not shown), thereby further suggesting that a hypothetical
cross-reactivity of CD8+ T cells against non-spliced PlcB-
derived epitopes to the spliced epitopes, or the other way
around, was unlikely.
To confirm that the specific CD8+ T cell-mediated response
toward the spliced epitopes in infected mice was the outcome
of the infection, we compared the frequencies of spliced
epitope-specific IFN-g+ CD8+ T cells among splenocytes of in-
fected mice to those of uninfected mice. For both the spliced
(PlcB189–191/163–167 and PlcB189–192/164–167) and non-spliced
(LLO296–304) epitopes, we observed a significantly larger preva-
lence of IFN-g+ CD8+ T cells in samples from infected mice
compared to those from uninfected mice (Figure 4B), suggesting
that the identified PlcB-derived spliced epitopes participate in
the priming of CD8+ T cell responses upon L. monocytogenes
infection.
To prove that the identified spliced epitopes are processed
from the PlcB protein and presented in vivo, EL4 cells (H-2Kb)
were transduced with retroviral constructs expressing either
full length PlcB or a mutated form of PlcB (PlcB-delta), in which
the spliced epitopes’ anchor residues were substituted for serine
residues (F164S and L167S: PlcB189–192/164–167 mutated to
ISYPSYKS and PlcB189–191/163–167 mutated to ISYASYKS), to
interfere with H-2Kb binding (Table 1). These EL4 cells, as well
as control EL4 cells transduced with an empty vector (Figure 5A)
or EL4 cells expressing LLO1–415, were co-cultured with purified
CD8+ splenocytes derived from PlcB-spliced epitope-respon-
sive infected (Figure 3) or uninfected mice. Activation-induced
IFN-g release by CD8+ T cells was quantified. As shown in Fig-
ure 5B, CD8+ T cells derived from infected mice were activated
by co-culture with EL4-LLO and EL4-PlcB cells, or by incubation
with identified spliced epitopes (shown in Figure 3), but not by
co-culture with PlcB-delta-expressing ormock transduced cells.
Thus, disruption of spliced epitope presentation on H-2Kb mole-
cules in EL4-PlcB-delta cells abrogated the ability of these cells
to trigger IFN-g production in PlcB-specific CD8+ T cells derived
from infected mice (Figure 5B). This indicates that these T cells
recognize the spliced epitope sequences on EL4-PlcB cells
and are not directed to peptides derived from another part of
PlcB or from a different Listeria protein. As expected, CD8+ sple-
nocytes derived from non-infected mice failed to respond to any
transduced EL4 cell line.
To exclude a theoretical cross-reaction of the spliced epitope-
specific CD8+ T cells against other spliced and non-spliced pep-
tides generated by proteasomes from the epitope surrounding
sequences, we analyzed PlcB159–171/185–196 digestion products
(Figure S3) by MS for the presence of other peptide products
that carried one of the two residues substituted in the PlcB-
delta, i.e., F164 or L167. Three non-spliced and ten spliced
peptides containing PlcB F164 and/or L167 were identified
(Table S1). We already demonstrated that the spliced epitopes
PlcB189–191/163–167 and PlcB189–192/164–167 activated the CD8
+
T cells of infected mice, whereas the non-spliced peptides
PlcB160–167 did not (Figure 4A). Among the other peptide pro-
ducts, only the spliced peptide PlcB187–191/164–167 was predicted
to bind the H-2Kb complex with an IC50 lower than 100 nM, i.e.,
73 nM, which is much larger than the IC50 of the overlapping
spliced epitopes PlcB189–191/163–167 and PlcB189–192/164–167 and
also than the IC50 of the spliced epitope candidates tested nega-
tive for recognition by CD8+ T cells of Listeria-infected mice
Table 1. Predicted Spliced Epitope Candidates
Peptidea Sequence IC50 (nM)
b T1/2 (hr)
c
LLO296–304
d VAYGRQVYL 8 1.4 ± 0.2
PlcA70–72/92–96 MSYLYQQL 2.5 –
PlcA70–73/93–96 MSYNYQQL 3.2 –
PlcA262–266/273–275 TSLTFAAL 3.5 –
PlcA262–267/285–286 TSLTFTNL 5.7 –
PlcA262–268/254 TSLTFTPL 6.7 –
PlcA70–72/57–61 MSYNLAAL 5.3 –
PlcA262–266/284–286 TSLTFLNL 7.3 –
PlcA112–114/92–96 KIYLYQQL 8.4 –
PlcA19–23/59–61 CFFTFAAL 3.8 –
PlcA19–23/56–58 CFFTFTNL 6.1 –
PlcA19–23/50–52 CFFTFSAL 8.7 –
PlcA19–24/57–58 CFFTFPNL 7.0 –
PlcB189–191/163–167 ISYAFYKL 1.1 5.25 ± 0.92
PlcB189–192/164–167 ISYPFYKL 1.9 4.05 ± 1.07
PlcB171–173/163–167 IHYAFYKL 6.1 2.39 ± 0.71
PlcB65–69/88–90 VNTHYANL 7.5 4.78 ± 1.69
PlcB189–191/181–185 ISYMHANN 8.0 0.17 ± 0.12
PlcB171–174/164–167 IHYYFYKL 8.1 1.66 ± 0.63
PlcB251–255/270–272 KSYLVARL 8.6 3.13 ± 0.56
PlcB118–121/137–140 STFLFANA 9.9 1.54 ± 0.25
PlcB189–192/182–185 ISYPHANN 11.6 0.22 ± 0.14
PlcB177–179/163–167 ISQAFYKL 15.4 1.43 ± 0.73
PlcB160–167
e FDTAFYKL 2949 –f
PlcB189–196
e ISYPPGYH 10840 –f
PlcB189–191/163,164S–167S
g ISYASYKS 288 –
PlcB189–192/164S–167S
g ISYPSYKS 473 –
aSpliced epitope candidates PlcA and PlcB antigens were predicted by
applying the in silico computation method shown in Figure 1.
bThe predicted IC50 for binding to the H-2K
b MHC class I molecule was
calculated using SMM algorithm (Peters and Sette, 2007).
cThe H-2Kb-peptide complex stability was empirically measured; mean
half-life (T1/2) and SD of two independent experiments are shown.
dThe half-life of LLO296–304 was in agreement with previous studies
(Platteel et al., 2016).
eThe two non-spliced peptides listed here were used as negative con-
trols, to exclude potential cross-reactivity of spliced epitope-specific
CD8+ T cells.
fPeptides failed to stabilize H-2Kb molecules.
gIn these spliced PlcB sequences, residue 164F and 167L were replaced
for S residues, to decrease H-2Kb binding affinity.
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(Figures S2 and 3 and see correlation between the frequency of
the IFN-g+ CD8+ T cells and the IC50 described below).
From these diverse control experiments, and the in vitro diges-
tion experiments (Figure S4), we infer that cells expressing the
Listeria PlcB protein generate the two PlcB-derived spliced epi-
topes in similar amounts (Figure S4) and present at least one of
them to CD8+ T cells, triggering T cell activation. Given the
absence of a CD8+ T cell response (1) toward the spliced PlcB
epitopes in uninfected mice, (2) toward a non-spliced peptide
sharing part of the spliced epitope sequence in infected mice,
and (3) toward EL4 cells expressing a PlcB variant in which the
MHC class I anchor sites of the two spliced epitopes are
mutated, the possibility of cross-reactivity of the spliced PlcB
epitope-specific CD8+ T cells is unlikely. This is further sup-
ported by the absence of other peptides produced by protea-
somes and predicted to efficiently bind to H-2Kb molecules.
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Figure 3. CD8+ T Cells from Infected Mice Specifically Recognize PlcB Spliced Epitopes
C57BL/6 mice were infected with L. monocytogenes, and 7 days later the frequency of CD8+ T cells specific for synthetic peptides among the splenocytes of
infected mice was measured ex vivo by intracellular staining of IFN-g in CD8+ T cells.
(A) Representative FACS plots of the staining in presence or absence of the target peptide LLO296–304.
(B) Frequency of IFN-g+ CD8+ T cells, upon ex vivo stimulation with the PlcA- or PlcB-spliced peptides and the non-spliced LLO296–304 epitope, among sple-
nocytes derived from infected mice (n = 5–43). Accumulated data of five independent experiments are shown, corrected for IFN-g background measured in
control samples incubated without peptide. The violin plots indicate the density of the measurements on each side, with all single mice indicated as dots. Red
lines indicate the median of the measurements. Significant differences between the splenocytes incubated with or without the peptides are marked as * (ANOVA
with Bonferroni and Welch’s corrections; LLO296–304, PlcB189–191/163–167, and PlcB189–192/164–167, p < 0.001).
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Measured H-2Kb-Spliced Peptide Stability and the
Predicted Binding Affinity Correlate with the Relative
Frequency of Specific CD8+ T Cells in Infected Mice
During the development of our in silico strategy for selecting the
best peptide candidates for this study, we assumed, based on
earlier studies (Sijts and Pamer, 1997; van der Burg et al., 1996;
Watson et al., 2012), a correlation between the predicted IC50
(i.e., H-2Kb binding affinity) and the recognition of peptides by
specific CD8+ T cells. Therefore, we restricted the list of spliced
peptides that might be recognized during L. monocytogenes
infection by their predicted IC50. The validity of this approach
was evaluated on the results of the ex vivo stimulation of spleno-
cytes derived from infected mice with the PlcB-spliced peptides
(Figure 6). In agreement with our assumption, we observed a sig-
nificant inverse correlation between the predicted IC50 of the
spliced peptides and the specific response (measured as fre-
quency of IFN-g+ CD8+ T cells ex vivo) in infectedmice (Figure 6A;
Table 1).
As proof of principle, we experimentally measured another
parameter depicting theaffinity betweenMHCclass I andpeptide,
i.e., the stability of H-2Kb-peptide complexes at the cell surface
of RMA-S cells (Figure 6B). Five out of ten spliced PlcB
epitope candidates tested, including PlcB189–191/163–167 and
PlcB189–192/164–167, upregulated H-2K
b levels on RMA-S cells
(Figure 6C, left panel), indicating that these peptides bound to
and stabilized RMA-S-expressed H-2Kb molecules. The other
spliced epitope candidates tested (Figure 6C, right panel) as well
as the non-spliced peptides PlcB160–167 and PlcB189–196 (data
not shown), only weakly upregulated or failed to upregulate
H-2Kb onRMA-S cells. This difference in peptide binding capacity
was illustrated by the half-lives that we computed based on chase
analyses of peptide-pulsed RMA-S cells (Table 1), which varied
from 5.25 hr for H-2Kb complexed with ‘‘strong’’ binders to
0.17 hr for weak binders. Of note, the two identified spliced epi-
topes PlcB189–191/163–167 and PlcB189–192/164–167 were among the
three highest affinity H-2Kb binders (Table 1), with computed
half-lives exceeding these of H-2Kb molecules bound to the con-
trol epitope LLO296–304. Comparing the data for all spliced pep-
tides tested, we found a significant inverse correlation between
the predicted IC50 and the measured half-lives of H-2K
b-peptide
complexes at the cell surface (Figure 6D). Accordingly, we also
found a significant direct correlation between the half-lives of
H-2Kb-peptide complexes and the relative frequency of IFN-g+
CD8+ T cells among infected mouse’ splenocytes for the spliced
peptides derived from PlcB (Figure 6E). Thus, selection of spliced
epitope candidates based on predicted IC50 is a valid approach
for focusing ex vivo analyses on the most promising epitope
candidates.
DISCUSSION
We here present a multi-level spliced epitope identification
approach that will be instrumental in uncovering the role of
PCPS in immune recognition, both of pathogen-derived and
self-antigens. Application of this approach enabled us to gain
insight into the contribution of PCPS to MHC class I antigen pro-
cessing. Focusing on two L. monocytogenes proteins as model
antigens, we show that PCPS generates two overlapping spliced
epitopes that participate in CD8+ T cell priming following infec-
tion. The precise contribution of the two respective peptides to
CD8+ T cell activation will be unraveled in future experiments
aimed at examining the MHC class I presentation kinetics of
the spliced epitopes in relation to each other as well as to other,
non-spliced Listeria epitopes.
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A B Figure 4. PlcB-Spliced Epitope-Specific
CD8+ T Cells Are Not Cross-Reactive to
PlcB Non-spliced Peptides and Are Not
Activated in Uninfected Mice
(A) Frequency of IFN-g+ CD8+ T cells, upon
ex vivo stimulation with the PlcB189–191/163–167-
and PlcB189–192/164–167-spliced epitopes and the
PlcB160–167 and PlcB189–196 non-spliced peptides,
among splenocytes derived from L. monocytogenes
infected mice (n = 18–37) is shown. Accumulated
data of five independent experiments are shown
per peptide corrected for IFN-g background
level as measured in control samples that
were incubated without peptide. The violin
plots indicate the density of the measurements on
each side, with all single mice indicated as dots.
Red lines indicate the median of the measurements.
Significant differences between the splenocytes
incubated with spliced epitopes and non-spliced
peptides are marked as * (ANOVA upon Bonferroni
and Welch’s corrections; PlcB 189–191/163–167 or
PlcB189–192/164–167 versus PlcB160–167 or PlcB189–196,
p < 0.001).
(B) Frequency of IFN-g+ CD8+ T cells, upon ex vivo
stimulation with LLO296–304, PlcB189–191/163–167, and
PlcB189–192/164–167, among splenocytes derived
from infected (n = 37–40) or uninfected (n = 3) mice.
Accumulated data of five independent experiments are shown. Significant differences between infected and uninfected mice are marked as * (t-student
with Welch’s correction; LLO296–304, and PlcB189–191/163–167, p < 0.001; PlcB189–192/164–167, p = 0.001).
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The method developed for this study to identify spliced
epitope candidates uses an in silico-guided approach for the
identification of spliced peptides, combined with experimental
outcomes and the SMM prediction algorithm. As part of this
approach, in silico-predicted epitope candidates are selected
based on their low predicted IC50, which showed to be the right
approach since we observed a correlation between predicted
IC50 (and H-2K
b-peptide complex stability) and the expansion
of specific CD8+ T cells during infection, in agreement with earlier
published works (Sijts and Pamer, 1997; van der Burg et al.,
1996; Watson et al., 2012).
The demonstration that proteasome-generated spliced epi-
topes trigger a specific CD8+ T cell response during
L. monocytogenes infection in mice could represent a mile stone
in the investigation of T cell immunity against pathogens. The
ability of PCPS to expand the epitope variety could be a key
means of the immune system to tackle the high mutation fre-
quency and therewith the escape mechanisms of some patho-
gens. The enormous number of potential combinations of
spliced peptides derived from an antigen could also be a means
for allowing the immune system to target antigens with few or
none non-spliced antigenic peptides that could be effectively
presented by the MHC class I molecules of a person.
Thus, the so-far neglected possibilities for epitopes gener-
ated by PCPS may be a tremendous asset for vaccination ap-
proaches focusing on single pathogen-derived proteins. To
illustrate this, we performed a preliminary in silico analysis to
identify PlcA and PlcB epitope candidates for the most frequent
human MHC class I haplotypes (Figures S5 and S6). We calcu-
lated that the number of potential spliced peptides predicted to
bind with high affinity to the most frequent HLA-A or HLA-B
variants largely exceeds that of the non-spliced peptides.
Thus, no non-spliced epitope candidates with a predicted
IC50 below 100 nM were found in PlcB or in PlcA in combina-
tion with HLA-A*01:01, HLA-A*03:01, HLA-B*44:02, or HLA-
B*44:03, while four and three non-spliced candidates were pre-
dicted for the PlcA antigen in combination with HLA-A*02:01
and HLA-B*07:02, respectively. In contrast, there are hundreds
of potential spliced epitopes for both antigens predicted to bind
to each of the investigated MHC class I haplotypes (Figures S5
and S6).
In conclusion, we suggest that spliced peptides might provide
immunological targets as well as a key means by which the im-
mune system tackles pathogens.
EXPERIMENTAL PROCEDURES
In Silico Generation of Spliced Peptide Target List
Given the PlcA (AEO05212.1) or PlcB (AEO05216.1) sequences, we first
computed all potential non-spliced and spliced peptides of length L = 8 and
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Figure 5. Identified PlcB-Spliced Epitopes Are Processed and Presented by EL4 Cells Expressing the L. monocytogenes-Derived PlcB
Protein
(A) Representative plot of GFP expression by EL4 cells transduced with retroviral vectors carrying the GFP gene and the target constructs PlcB and PlcB-delta.
Mock: empty-vector-transduced cells.
(B) Purified CD8+ splenocytes of infected and uninfected mice were co-cultured with EL4 cells transduced with LLO1–415, PlcB, PlcB-delta or the empty vector
(mock). After 48 hr the supernatants were collected and IFN-g was quantified (pg/mL). The data of one experiment with a pool of ten animals, representative of
three independent experiments (total n = 48), performed with thawed and fresh CD8+ splenocytes, are shown (red bars: means). Significant differences in IFN-g
release by splenocytes of infected mice co-cultured with LLO versus mock cells (p = 0.0025), PlcB versus mock cells (p = 0.0187), and PlcB versus PlcB-delta
cells (p = 0.0328) are marked as * (t-student with Welch’s correction).
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L = 9, resulting in N peptides, denoted as [n-p1]/[p2-c], where N can be ob-
tained via Equation 1 derived from Liepe et al. (2010).
N=
X9
L= 8
XS
n= 1
Xn+ L2
p1= n
XS­L+p1n+1
p2
1; (Equation 1)
where S is the length of the parental antigen (PlcA and PlcB, respectively). This
list was then reduced by excluding all spliced peptides generated through
trans PCPS. This means that for a given spliced peptide denoted as [n-p1]/
[p2-c] all peptides with p1 < p2 (for PCPS in same order as in parental antigen)
or c < n (for PCPS in reverse order compared to the parental antigen) are
maintained in the reduced database). We next removed all peptides with
intervening sequence length l larger than 40 amino acids, where l is defined
as l = p2-p1-1 for splicing in normal order, and l = c-n-1 for splicing in reverse
order. For all remaining 8- and 9-mer spliced peptides, we computed in silico
the IC50 as a measure for binding strength to the murine H-2K
b or the human
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Figure 6. Correlation between Predicted IC50, H-2K
b-Peptide Stability, and Frequency of Specific CD8+ T Cells in Infected Mice
(A) Correlation between the predicted IC50 of PlcB-spliced peptides and the frequency of IFN-g
+ CD8+ T cells specific for the peptides among splenocytes derived
from L. monocytogenes infected mice (for all PlcB peptides tested on five to 37 mice). There is a significant inverse correlation (Spearman correlation test
p < 0.001, C value = 0.559). Values are the mean and bars the SEM of tested mice for each peptide (n = 5–37). IC50 of the peptides for the H-2Kb complex was
predicted by the SMM algorithm (Peters and Sette, 2007).
(B) H-2Kb-peptide stability was measured with RMA-S cells incubated with synthetic peptides and chased in the absence of peptide. At different time points the
remaining H-2Kb-peptide complexes were measured using FACS and measured in MFI (mean fluorescence index).
(C) The stability of the H-2Kb complexes bound to each PlcB-spliced peptide is shown. Peptides were divided in strong binders (with MFI > 500 at t = 0; left panel)
or weak binders (with MFI < 200 at t = 0; right panel). Incubation without peptide resulted in a background MFI level of40. Values are the mean MFI ± SD of two
independent experiments.
(D) Correlation between the predicted IC50 of the PlcB-spliced peptides (n = 10) and the H-2K
b-peptide half-life at the cells surface is shown. Values are the mean
of two independent experiments. There is a significant inverse correlation (Spearman correlation test p = 0.022, C value = 0.709).
(E) Correlation between the H-2Kb-peptide stability and the frequency of IFN-g+ CD8+ T cells responsive against the spliced peptides among splenocytes derived
from infected mice (for all peptides tested on five to 37 mice). There is a significant correlation (Spearman correlation test p < 0.001, C value = 0.498). Values are
the mean and bars the SEM of mice tested for each peptide (n = 5–37).
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HLA-B*44:03 haplotypes using the offline version of the SMM algorithm
(Peters and Sette, 2007). We considered all spliced peptides with predicted
IC50 <100 nM and a further IC50 cutoff of 16 nM.
Peptide Synthesis and 20S Proteasome Purification
The PlcB159–171/185–196 (KFDTAFYKLGLAINFTAISYPPGYH) polypeptide sub-
strate and all non-spliced and spliced PlcA and PlcB peptides were synthe-
sized using Fmoc solid phase chemistry. 20S proteasomes were purified
from five pooled spleens of C57BL/6 mice infected or uninfected by
L. monocytogenes (Platteel et al., 2016). The purity of the proteasome prepa-
ration is shown in Figure S7. The differences in proteasome subunit composi-
tion were described previously (Platteel et al., 2016).
Identification and Quantification of Peptide Products from In Vitro
Digestions by Proteasomes
PlcB159–171/185–196 (20 mM) was digested by 2 mg 20S proteasomes in 100 mL
TEAD buffer (Tris 20 mM, EDTA 1 mM, NaN3 1 mM, DTT 1 mM [pH 7.2])
over time, at 37C. Identification of the polypeptide digestion products was
performed by liquid-chromatography mass spectrometry (LC-MS) analyses:
15-mL digested samples were analyzed directly by nanoscale LC-MS/MS
using an Ultimate 3000 and LTQ Orbitrap XL mass spectrometer (Thermo
Fisher Scientific). The system comprises a 5-mm 3 300-mm, 100-A˚ trapping
column (PepMap C18, 5 mm; Dionex) and a PicoChip analytical column
(Reprosil-pur; 3 mm; New Objective). The mobile phase (A) was 0.1% (v/v)
formic acid in water and (B) was 80:20 (v/v) acetonitrile/water containing
0.1% (v/v) formic acid. Elution was carried out using a gradient 15%–50% B
in 35 min with a flow rate of 300 nL/min. Full MS spectra (m/z 300–2,000)
were acquired in an Orbitrap instrument at a resolution of 60,000 (full width
at half maximum [FWHM]). At first, the most abundant precursor ion was
selected for either data-dependent collision-induced dissociation (CID) frag-
mentation with parent list (1+, 2+ charge state included). Fragment ions were
detected in an Ion Trap instrument. Dynamic exclusion was enabled with a
repeat count of 2- and 60-s exclusion duration. Additional, the theoretically
calculated precursor ions of the expected spliced peptides were pre-elected
for twoOrbitrap CID (m/z 350–2,000) and higher energy collisional dissociation
(HCD; m/z 100–1500) fragmentation scans. The maximum ion accumulation
time for MS scans was set to 200 ms and for MS/MS scans to 500 ms. Back-
ground ions at m/z 391.2843 and 445.1200 act as lock mass. Peptides were
identified by PD1.4 software (Thermo Fisher Scientific) based on their merged
tandem mass spectra (MS/MS) of CID and HCD. In addition, for spliced pep-
tides we compared the retention time and the mergedMS/MS of CID and HCD
with the fragmentation pattern of their synthetic counterparts. The database
used for the LC-MS/MS analyses was generated by applying the SpliceMet’s
ProteaJ algorithm thereby allowing the identification of non-spliced and
spliced peptides (Liepe et al., 2010).
The polypeptide digestion kinetics were analyzed with the ESI-ion trap in-
strument DECA XP MAX (Thermo Fisher Scientific) as described (Liepe
et al., 2010). The quantification of peptides produced in the in vitro digestion
kinetics was carried out by applying the QME method to the LC-MS analyses
(Mishto et al., 2012). QME estimates the absolute content of spliced and non-
spliced peptide products based on their MS peak area measured in the diges-
tion probe. The QME algorithm parameters were empirically computed in our
previous study (Mishto et al., 2012) and here applied.
Cell Culture
RMA-S cells were cultured in IMDM (Invitrogen Life Technologies), supple-
mented with 10% fetal calf serum (FCS; LONZA), 2 mM L-glutamine, 30 mM
2-ME, and 100 U/mL penicillin/streptomycin. 293T cells were maintained in
DMEM (Invitrogen Life Technologies) supplemented with 10% FCS and peni-
cillin/streptomycin. Transduced EL4 cells were cultured in RPMI (Invitrogen
Life Technologies), supplemented with 10% FCS, 2 mM L-glutamine, 30 mM
2-ME, penicillin/streptomycin, and 5 mg/mL puromycin (Sigma-Aldrich) as
appropriate.
MHC Class I Peptide Stability Assays
RMA-S off rate assays were performed as described (Deol et al., 2007).
In short, TAP-deficient RMA-S cells were incubated overnight (o/n) in the
presence or absence of 100 mM synthetic peptide, at 37C. Cells were
harvested, washed three times with PBS, and chased in the absence of pep-
tide, at 37C, stained for H-2Kb class I expression with a conformation-sensi-
tive, biotin-conjugated mouse antibody (Ab) (AF6-88.5; BD Bioscience) and
PE-conjugated SA (eBioscience) and analyzed using fluorescence-activated
cell sorting (FACS) Canto II (BD Bioscience) and FlowJo software (Tree Star).
The T1/2 of the H-2K
b-peptide complex at the cell surface was computed as
described (Textoris-Taube et al., 2015), based on the mean fluorescence
levels of peptide-pulsed cells corrected for background levels from cells that
were not incubated with peptide.
Retroviral Transduction of EL4 Cells
LLO1–415 was amplified from L. monocytogenes 10403S using forward
primer AGATCTGTGAAACCCATGAAAAAAATAATGCTAG and reverse primer
TTAATCTGTATAAGCTTTTGAAGTTGTTTC. The product was verified by
sequencing and cloned into a pMSCV_IRES_GFP vector (Addgene). Synthetic
DNA sequences of PlcB and PlcB-delta (with the substitutions F164S and
L167S) were purchased (Geneart Invitrogen) and cloned into pMSCV-Puro-
IRES-GFP. pMSCV constructs and pCl-10A1, encoding the envelope proteins,
were transfected into 293T cells using Lipofectamine 2000 reagent (Thermo
Fisher Scientific) as instructed. After 24 hr, the medium was removed and cells
were co-culturedwith EL4 cells, added in 10mLmedium, for 48 hr at 37C. EL4
cells were then harvested, resuspended in 10 mL DMEM medium without
(LLO-transduced cells) or with puromycin (PlcB, PlcB-delta and mock cells).
Expression of the constructs was verified by GFP expression using FACS
and found to be 99% (Figure 5A) for PlcB, PlcB-delta, and mock cells.
LLO-expressing cells were sorted by FACS twice, which resulted in expression
levels of 20%.
Mice and Infection
L. monocytogenes strain 10403S was grown in brain-heart infusion medium
(Sigma-Aldrich) and harvested while in log phase. C57BL/6 mice were pur-
chased from Charles River. For infection, 6 to 8-week-old female mice
were inoculated intravenously in the tail vain with 2000 bacteria (0.1 LD50)
in 200 mL PBS. All animal experiments were approved by the Animal
Ethics Committee from Utrecht University (DEC 2014.II.11.081 and DEC
2014.II.01.003).
Intracellular IFN-g Staining
Erythrocyte-depleted single spleen cell suspensions were prepared and
0.5 3 106 splenocytes were incubated with or without 1 mg/mL synthetic pep-
tide for 6 hr in 1 mL RPMI medium, containing 50 mg/mL gentamycin (Gibco),
and 10 mMmonensin (eBioscience), at 37C. Subsequently, cells were stained
with an antigen-presenting cell (APC)-conjugated anti-mouse CD8 antibody
(53-6.7; eBioscience) in the presence of anti-mouse CD16/CD32 antibody
(clone 2.4G2; made in house). Cells were fixed with 2% paraformaldehyde
and then stained with phycoerythrin (PE)-conjugated anti-mouse IFN-g anti-
body (XMG1.2; eBioscience) in the presence of 0.5% saponin and analyzed
on a FACS Canto II (BD Biosciences) using FlowJo software (Tree Star). Per-
centages of specific IFN-g+ CD8+ splenocytes were calculated by subtracting
the background IFN-g+ CD8+ level of splenocytes incubated without peptide
per individual mouse.
Detection of IFN-g Release
CD8+ splenocytes were enriched by negative selection for CD4 (GK1.5), B220
(RA3-6B2), CD11b (M1/70), and MHCII (M5/114)-expressing cells using
Dynal beads (Invitrogen). 4 3 105 CD8+ cells (purity 80%) were co-cultured
with 2 3 105 transduced EL4 cells for 48 hr, and supernatants were then
collected for analysis in a monoplex IFN-g assay using the Magpix (Luminex
XMAP) system, as instructed. Briefly, supernatant were incubated o/n with
magnetic IFN-g capture beads (clone AN-18), in 96-well flat-bottomed
plates (Greiner bio-one, 655096). Captured IFN-g was detected with biotin-
conjugated anti-IFN-g mAb (clone XMG1.2) and Streptavidin-PE. Cytokine
concentrations in the tested samples were calculated from a standard
curve generated with rIFN-g and MFI data were analyzed using a 5-parameter
logistic method (xPONENT software, Luminex).
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Statistical Analysis
Data were tested for normality distribution and homoscedasticity by Kolmo-
gorov-Smirnov, Shapiro-Wilk, and Levene tests. To test for significant differ-
ences between CD8+ T cell responses to different epitope candidates, we
applied an unpaired ANOVA test with Bonferroni post hoc correction for
multiple comparisons and Welch’s correction. To compare frequencies of
peptide-specific CD8+ T cells between infected and uninfected mice, we
applied an unpaired t test with Welch’s correction. The same test was per-
formed in Figure 5 to compare INF-g release by CD8+ T cells toward EL4 cells
expressing LLO, PlcB, PlcB-delta as compared to those expressing the empty
vector (mock). For the correlations, we applied a Spearman test. p < 0.05 was
considered to be significant.
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